The understanding of the pathophysiology of TSC was crucial to the use of mTOR inhibitors to treat this disorder, opening avenues for the identification of novel therapeutic targets and medicines with higher efficacy and fewer adverse effects to modify the course of the disease. This evidence concerns the gene MTOR and tuberous sclerosis.